Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes

We are excited to announce that Takara Bio Europe AB (TBEAB) will be supporting PanCryos’ efforts to develop a cell-based therapy for diabetes through the out-licensing of Takara Bio’s new clinical-grade hES cell line. In a new press release, Jacqueline Ameri, CEO of PanCryos said, “We are very hopeful that our extensive scientific and industry expertise, combined with TBEAB’s expertise in clinical-grade hES cell production, will put us in a position to take the crucial next step in the development of our best-in-class, commercially sustainable PanINSULA™ cell therapy for type 1 diabetes.”

Takara Bio’s new out-licensing program provides researchers across the world access to the first human ES cell line to be derived under GMP conditions and very stringent criteria. Starting material was sourced from prion-free regions, and donors were tested within 7 days of starting material retrieval and according to FDA guidelines. With such rigorous quality and safety standards, "our customers know they can rely on us for high-quality, safe starting material for their cell therapy development,” Site Head and Senior Director at TBEAB Kristina Runeberg said.

Read the full release »